about
HIV Genome-Wide Protein Associations: a Review of 30 Years of ResearchViruses Utilize Cellular Cues in Distinct Combination to Undergo Systematic Priming and UncoatingVesicular Trafficking to the Immune Synapse: How to Assemble Receptor-Tailored Pathways from a Basic Building SetSynthetic Peptides as Protein MimicsMaraviroc: a review of its use in HIV infection and beyondConformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1Diversity and Inter-Connections in the CXCR4 Chemokine Receptor/Ligand Family: Molecular PerspectivesNew insights into the pathology of podocyte loss: mitotic catastropheHIV-1 envelope glycoprotein structureHIV-1 reverse transcriptionLine tension at lipid phase boundaries as driving force for HIV fusion peptide-mediated fusion.Fusion of Enveloped Viruses in Endosomes.HIV-1 gp120 as a therapeutic target: navigating a moving labyrinthFunctional organization of the HIV lipid envelopeRecent Insights into the HIV/AIDS Pandemic.Chimeric Cyanovirin-MPER recombinantly engineered proteins cause cell-free virolysis of HIV-1.Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist.Engineering antibody-like inhibitors to prevent and treat HIV-1 infection.Strength of Neisseria meningitidis binding to endothelial cells requires highly-ordered CD147/β2-adrenoceptor clusters assembled by alpha-actinin-4.The Membrane-Proximal Region of C-C Chemokine Receptor Type 5 Participates in the Infection of HIV-1.HIV-1 Nef Signaling in Intestinal Mucosa Epithelium Suggests the Existence of an Active Inter-kingdom Crosstalk Mediated by Exosomes.Mechanisms of Virologic Control and Clinical Characteristics of HIV+ Elite/Viremic ControllersQuantitative phosphoproteomics reveals extensive cellular reprogramming during HIV-1 entry.Glycan-protein interactions in viral pathogenesisHIV Nef and Vpu protect HIV-infected CD4+ T cells from antibody-mediated cell lysis through down-modulation of CD4 and BST2.Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.Enhanced potency of bivalent small molecule gp41 inhibitors.Human coronavirus NL63 utilizes heparan sulfate proteoglycans for attachment to target cellsAnalysis of Social and Genetic Factors Influencing Heterosexual Transmission of HIV within Serodiscordant Couples in the Henan CohortA Conserved Glycan in the C2 Domain of HIV-1 Envelope Acts as a Molecular Switch to Control X4 Utilization by Clonal Variants with Identical V3 Loops.Periluminal Distribution of HIV-Binding Target Cells and Gp340 in the Oral, Cervical and Sigmoid/Rectal Mucosae: A Mapping Study.HIV-1 antiretroviral drug therapy.HIV-1 Env and Nef Cooperatively Contribute to Plasmacytoid Dendritic Cell Activation via CD4-Dependent MechanismsEvolution of coreceptor utilization to escape CCR5 antagonist therapy.Optimal management of cervical cancer in HIV-positive patients: a systematic review.Altered Immune Cytokine Expression Associated with KoRV B Infection and Season in Captive Koalas.Assembly and characterization of gp160-nanodiscs: A new platform for biochemical characterization of HIV envelope spikes.Comparative mapping of host-pathogen protein-protein interactions.Affinofile profiling: how efficiency of CD4/CCR5 usage impacts the biological and pathogenic phenotype of HIVHIV-1 pathogenesis: the virus.
P2860
Q26746070-B3AD3FB5-4B6F-4B6B-AC0F-0DC2C9AAF220Q26750943-9476B92B-4454-46B9-B327-F388B005C2B5Q26766480-F2ACB02C-5C84-4FDB-8525-B09D82219002Q26770255-6E4419FF-C930-4B44-8E64-01F2AEB40941Q26778504-1C681397-FE18-490A-97CF-96E6BD3F497FQ26782237-97E5C669-67BA-4EF4-9860-AFA411F144F4Q26782778-0145532D-7CE8-4613-A05E-EDED12E42DF9Q26991667-43B12BC3-F091-4578-BD8B-0F691EBF8850Q27011248-E2337FD1-1336-48BC-B17B-1710E3E58D80Q27023387-534DD851-61D9-4ACF-8BC0-4FAF0D4927CEQ27318758-70EA8B9A-A028-457F-8259-31D23EA1833DQ28073406-B35962D9-D15B-4E2D-B181-017D303AF368Q28086826-9D48C717-B0BA-4155-8CEB-FF42E1748650Q28828700-A5A100CA-5270-4F8B-83E0-06BBE9795B35Q30235024-BB58BA61-DFEF-47AE-BEAA-3CB95C5574BCQ30352110-747928DD-8914-49E9-AFB1-E74167B15B48Q30358736-5108C1DF-55B9-4635-8DD4-4153756E0E63Q30490945-CED0FB12-4B82-4C09-8CC1-0ABAF6AEDE48Q30855022-433034AF-3532-4173-A82F-B649B8470FA7Q33595068-B4DB576D-3B73-4CC3-AC60-C09F319E4CE2Q33774685-C0ECCFEA-6216-4AA2-B416-9FA470E641CCQ33828507-D54515BE-7E4A-4AC9-97B8-FD480D117ECEQ33924420-3643FEFD-4C8B-4F91-80D2-2E526C97A1A7Q33926161-61C8A56E-BA45-4778-B479-75235C4BF103Q34402446-0D3A2368-C887-4156-A00E-DABAE9B52135Q34517381-B1EFD744-93CF-474B-826F-22B6AEA8BFA1Q34546445-6384D226-AC63-45FB-9019-7FCCF44A269BQ34594739-F0F2C8F8-ECE4-4687-B48C-1E69E27231D0Q35662042-3AC49754-A81C-498E-8FB5-5067A8A2DE4AQ35666270-706890B3-8580-4D0B-9B18-6888EEB356EEQ35850177-561161EA-7B5D-426D-8F59-667E755E8CA8Q35853012-4A11EC99-9007-4BEA-8FE7-4C38CB5EB399Q35861175-BBD925CB-002B-4E09-863A-9FCF7E30FE1EQ36003168-B5D990B7-34E5-4E1A-9135-1F218A73539FQ36051789-FC668DAD-9D5F-4F96-A391-702E22217726Q36153785-0634AA16-5758-462A-BF15-37C190F22F28Q36248882-819CCCA5-7C8A-4551-A7D8-57E60BA7F5C3Q36319585-6E0CED0E-7980-45A7-B4CF-C2726A565328Q36466404-D885D5BA-8896-40B4-AC07-E32FA93E87B2Q36526530-C3A692BC-1DBA-4089-92EB-FA1DCCBF0BFF
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
HIV: cell binding and entry
@ast
HIV: cell binding and entry
@en
HIV: cell binding and entry
@nl
type
label
HIV: cell binding and entry
@ast
HIV: cell binding and entry
@en
HIV: cell binding and entry
@nl
prefLabel
HIV: cell binding and entry
@ast
HIV: cell binding and entry
@en
HIV: cell binding and entry
@nl
P2860
P3181
P1476
HIV: cell binding and entry
@en
P2093
John C Tilton
Robert W Doms
P2860
P3181
P356
10.1101/CSHPERSPECT.A006866
P407
P577
2012-08-01T00:00:00Z